The online version of this article (doi:10.1186/s12879-017-2329-5) contains supplementary material, which is available to authorized users.
Vaccination against seasonal influenza strains is recommended for “high risk” patient groups such as infants, elderly and those with respiratory or circulatory diseases. However, efficacy of the trivalent influenza vaccine (TIV) is poor in many cases and in the event of an influenza pandemic, mono-valent vaccines have been rapidly developed and deployed. One of the main issues with use of vaccine in pandemic situations is the lack of a suitable quantity of vaccine early enough during the pandemic to exert a major influence on the transmission of virus and disease outcome. One approach is to use a dose-sparing regimen which inevitably involves enhancing the efficacy using adjuvants.
In this study we compare the use of a novel microcrystalline tyrosine (MCT) adjuvant, which is currently used in a niche area of allergy immunotherapy, for its ability to enhance the efficacy of a seasonal TIV preparation. The efficacy of the MCT adjuvant formulation was compared to alum adjuvanted TIV and to TIV administered without adjuvant using a ferret challenge model to determine vaccine efficacy.
The MCT was found to possess high protein-binding capacity. In the two groups where TIV was formulated with adjuvant, the immune response was found to be higher (as determined by HAI titre) than vaccine administered without adjuvant and especially so after challenge with a live influenza virus. Vaccinated animals exhibited lower viral loads (as determined using RT-PCR) than control animals where no vaccine was administered.
The attributes of each adjuvant in stimulating single-dose protection against a poorly immunogenic vaccine was demonstrated. The properties of MCT that lead to the reported effectiveness warrants further exploration in this and other vaccine targets - particularly where appropriate immunogenic, biodegradable and stable alternative adjuvants are sought.
Additional file 1: Weight loss analysis. (TIFF 88 kb)12879_2017_2329_MOESM1_ESM.tif
Shanta M, Zimmer MD, Burke DS. Historical Perspective — Emergence of Influenza A (H1N1) Viruses. NEJM. 2009;361:279–85. CrossRef
McGeogh D, Fellner P, Newton C. Influenza virus genome consists of eight distinct RNA species. Proc Natl Acad Sci U S A. 1976;73:3045–9. CrossRef
Gilca R, Skowronski DM, Douville-Fradet M, et al. Mid-season estimates of influenza vaccine effectiveness against influenza A (H3N2) hospitalization in the elderly in Quebec, Canada, January 2015. PLoS One. 2015;10(7):e0132195.
Cowling BJ, Feng S, Finelli L, Steffens A, Fowlkes A. Assessment of influenza vaccine effectiveness in a sentinel surveillance network 2010–13. United States Vaccine. 2016;34:61–6. PubMed
Park S-J, Kim E-H, Pascua PNQ, Kwon H-I, Lim G-J, Decano A, et al. Evaluation of heterosubtypic cross-protection against highly pathogenic H5N1 by active infection with human seasonal influenza A virus or trivalent inactivated vaccine immunization in ferret models. J Gen Virol. 2014;95:793–8. CrossRefPubMed
Chia M-Y, Hu AY-C, Tseng Y-F, Weng T-C, Lai C-C, Lin J-Y, et al. Evaluation of MDCK Cell-Derived Influenza H7N9 Vaccine Candidates in Ferrets. PLoS One. 2015;10
Wheeler AW, Moran DM, Robins BE, Driscoll A. L-Tyrosine as an Immunological Adjuvant. Int Arch Allergy Immunol. 1982;69:113–9. CrossRef
DuBuske LM1, Frew AJ, Horak F, Keith PK, Corrigan CJ, Aberer W, Holdich T, von Weikersthal-Drachenberg KJ.Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen. Allergy Asthma Proc. 2011;32(3):239–47.
Marriott AC, Dove BK, Whittaker CJ, Bruce C, Ryan KA, Bean TJ, Rayner E, Pearson G, Taylor I, Dowall S, Plank J, Newman E, Barclay WS, Dimmock NJ, Easton AJ, Hallis B, Silman NJ, Carroll MW. Low dose influenza virus challenge in the ferret leads to increased virus shedding and greater sensitivity to oseltamivir. PLoS One. 2014;9
de Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus AD. Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel). 2003;115:63–73.
Khong H, Sharma M, Dai Z, Singh M, Hailemichael Y, Overwijk W. L-tyrosine is a promising cancer vaccine adjuvant. J ImmunoTherapy of Cancer. 2015;3(2):1–1.
WHO Expert Committee on Biological Standardization Sixty-third report. Recommendations to assure the quality, safety and efficacy of tetanus vaccines (adsorbed) Replacement of Annex 2 of WHO Technical Report Series, No. 800, and Annex 5 of WHO Technical Report Series, No. 927.
O’Hagan DT, Fox CB. New generation adjuvants – From empiricism to rational design. Vaccine. 2015:B14–20.
Dimmock NJ, Dove BK, Scott PD, Meng B, Taylor I, Cheung L, Hallis B, Marriott AC, Carroll M, Easton AJ. Cloned defective interfering influenza virus protects ferrets from pandemic 2009 influenza A virus and allows protective immunity to be established. PLoS One. 2012;7:e49394. CrossRefPubMedPubMedCentral
Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine. 2001;21:2673–80. CrossRef
- Comparison of a novel microcrystalline tyrosine adjuvant with aluminium hydroxide for enhancing vaccination against seasonal influenza
M. D Heath
N. J. Swan
A. C. Marriott
N. J. Silman
K. E. Gooch
M. A. Skinner
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II